全球精神病学/抑郁症药物基因组学测试市场 – 行业趋势和 2031 年预测

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Medical Devices Global Pharmacogenetic Testing In Psychiatry Depression Market
请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球精神病学/抑郁症药物基因组学测试市场 – 行业趋势和 2031 年预测

  • Medical Devices
  • Published Report
  • Mar 2024
  • Global
  • 350 页面
  • 桌子數： 977
  • 图号： 48
立即购买 立即购买

>全球精神病学/抑郁症药物基因组学测试市场，按类型（焦虑、抑郁、情绪障碍、双相情感障碍、饮食失调和精神病）、产品（消耗品、仪器、软件和服务）、测试类型（基于全基因组测序和染色体阵列的测试）、基因类型（CYP2C19、CYP2C9 和 VKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT 等）、患者类型（成人、老年人和儿童）、最终用户（医院和诊所、诊断实验室、学术和研究机构等）、分销渠道（直接招标、第三方分销、医院药房等）划分 - 行业趋势和预测到 2031 年。

精神病学/抑郁症市场中的药物基因组学测试

精神病学/抑郁症药物基因组学检测市场分析与洞察

患有精神病和抑郁症的患者数量不断增加，预计将推动市场增长。个性化和精准医疗的需求不断增长，有助于促进市场增长。缺乏熟练的医学和基因组学专家以及缺乏强有力的临床证据可能会阻碍市场增长。然而，技术进步的不断进步有望为市场增长提供机会。

精神病学/抑郁症市场中的药物基因组学测试

精神病学/抑郁症市场中的药物基因组学测试

Data Bridge Market Research 分析，全球精神病学/抑郁症药物基因组学测试市场规模预计将从 2023 年的 12.2 亿美元增至 2031 年的 26.6 亿美元，在 2024 年至 2031 年的预测期内，复合年增长率为 10.4%。

报告指标

细节

预测期

2024 至 2031 年

基准年

2023

历史岁月

2022（可定制为 2016 – 2021）

定量单位

收入（十亿美元）和销量（单位）

涵盖的领域

类型（焦虑、抑郁、情绪障碍、双相情感障碍、饮食失调和精神病）、产品（耗材、仪器、软件和服务）、检测类型（全基因组测序和染色体阵列检测）、基因类型（CYP2C19、CYP2C9 和 VKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT 等）、患者类型（成人、老年人和儿童）、最终用户（医院和诊所、诊断实验室、学术和研究机构等）、分销渠道（直接招标、第三方分销、医院药房等）

覆盖国家

美国、加拿大、墨西哥、德国、英国、法国、意大利、荷兰、西班牙、俄罗斯、瑞士、土耳其、波兰、挪威、匈牙利、奥地利、爱尔兰、立陶宛、欧洲其他地区、中国、日本、印度、韩国、澳大利亚、新加坡、泰国、印度尼西亚、马来西亚、菲律宾、越南、亚太其他地区、巴西、阿根廷、秘鲁、南美洲其他地区、沙特阿拉伯、阿联酋、以色列、南非、埃及以及中东和非洲其他地区

涵盖的市场参与者

Thermo Fisher Scientific Inc.、Illumina Inc.、Myriad Genetics Inc.、Sonic Healthcare Limited、QIAGEN、AB-BIOTICS SA、BiogeniQ Inc.、Castle Bioscience Inc.、Coriell Life Sciences、Dynamic DNA Laboratories、Eurofins Scientific、Genelex、Genewiz、Genomind Inc.、GenXys、HealthSpek、HudsonAlpha、MD Labs、ONEOME LLC 和 PacBio 等

市场定义

药物遗传学测试研究药物与人体基因反应之间的相互作用，并寻找影响药物效果的基因变异。由于许多研究人员和科学家确定了药物与个体基因之间的独特相互作用，并提供了有价值的见解，随后可用于开发定制或个性化药物，因此该测试的需求量很大。

精神病学/抑郁症药物基因组学检测市场 动态

本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：     

驱动程序

  • 抑郁症患者人数不断增加

抑郁症是一种全球普遍存在的疾病，与正常的情绪变化不同。抑郁症可能成为一种严重的健康状况，从轻度到极度严重，给患者带来巨大痛苦，在最坏的情况下可能导致自杀。虽然有超过 45 种抗抑郁药可用，但反应不佳会带来困难，这被认为是基因变异的结果。

随着抑郁症患病率的上升，药物基因组学检测的需求也在增加，因为它可以研究基因变异的影响以提供定制治疗，从而推动市场增长。

  • 生物技术行业不断发展，医疗支出不断增加

人们越来越关注自己的健康，也越来越关注预防性医疗保健。医疗保健越来越受到重视。由于医疗保健系统中拥有先进的技术，例如先进的测试，了解疾病和症状对于筛查和早期发现疾病至关重要，这有助于医疗保健提供者并提高存活率。

生物技术行业的蓬勃发展，加上全球医疗支出的不断增长，预计将推动精神病学和抑郁症领域的药物基因组学检测市场的发展。随着生物技术公司开发出创新的检测方法和技术，人们对个性化医疗（包括药物基因组学检测）的关注度不断提高。再加上医疗支出的不断增长，这表明对先进医疗解决方案的投资不断增加，这些解决方案可以改善患者的治疗效果并降低整体医疗成本，从而推动市场增长。

精神病学/抑郁症市场中的药物基因组学测试

机会

  • 基因检测的进展

医疗保健领域正在经历快速的技术进步，特别是在开发新的和复杂的方法以促进药物遗传学检测方面。这些创新测试利用先进的基因检测方法来提供精确的结果，使医疗保健提供者能够更有效地定制治疗方案。这一进步为精神病学和抑郁症领域的全球药物遗传学检测市场提供了重要机会。随着这些尖端技术变得越来越普及和完善，它们有可能彻底改变个性化医疗，为患者提供更有针对性和更有效的精神健康状况治疗。

这些测试在建立药物与个人基因特征之间的有意义联系方面发挥着至关重要的作用。这种个性化方法可帮助医疗保健提供者为患有重度抑郁症和其他精神疾病的患者选择最合适的药物。通过利用基因检测方面的进步，药物遗传学检测可以显著提高治疗效果并改善精神病学和抑郁症患者的护理，这有望为市场增长创造机会。

限制/挑战

  • 临床验证不足

随着医学科学的进步，新的检测方法正在不断开发，以研制出有效治疗重度抑郁症的强效药物。治疗中使用的抗抑郁药和抗精神病药可能无效。它们可以帮助根据患者个人需求推荐可用于治疗疾病的药物。

尽管有这样的优势，但这些测试缺乏完全依赖的强大临床基础。尽管对小规模人群进行的研究显示出令人鼓舞的结果，但这些测试的有效性在更大范围的人群中尚无证据。

精神病学中的药物遗传学测试不会评估治疗结果中的不依从性。因此，当所考虑人群中的不依从率增加时，统计数据的效力就会降低，从而导致缺乏证据来证明测试的有效性。

缺乏完全依赖这些测试的基础是市场的主要缺点。患者更愿意坚持使用传统的测试方法，因此阻碍了市场的增长。

  • 对数据隐私和安全的担忧日益加剧

药物基因组学测试分析了个人的基因构成如何影响他们对药物的反应，这引起了人们对数据隐私和安全的极大担忧，尤其是在全球数据共享和存储的背景下。遗传信息本质上是个人信息，可以揭示个人健康的敏感细节，包括对某些疾病的易感性和对特定药物的反应。因此，如果没有得到充分保护，这些信息被滥用或不当访问的风险就会增加。

一个主要问题是基因歧视的风险，即个人可能因其基因信息而在就业或保险方面遭遇不利结果。数据泄露是另一个重大风险，特别是随着基因信息越来越多地跨境共享用于研究或临床目的。在隐私法规不同的司法管辖区之间转移数据可能会进一步使确保数据安全的努力复杂化。

由于遗传信息的敏感性，数据隐私和安全是精神病抑郁症市场药物遗传学测试全球实施面临的重大挑战，患者提供的数据可能被滥用或未经授权访问。数据的敏感性可能引发多个问题，预计这些问题将对市场增长构成挑战。

最新动态

  • 2024 年 2 月，基因检测和精准医疗领域的先驱 Myriad Genetics, Inc. 收购了 Intermountain Health 的 Precision Genomics (IPG) 实验室的部分资产。其中包括 Precise Tumor Test、Precise Liquid Test 和 IPG 位于犹他州圣乔治的 CLIA 认证实验室。此次收购使 Myriad 能够增强其肿瘤分析产品并扩大其肿瘤学产品组合，其中包括遗传性癌症和伴随诊断检测选项
  • 2024 年 2 月，QIAGEN 宣布其可持续发展工作获得了 My Green Lab 的认可，My Green Lab 是一家致力于促进科学研究可持续性的非营利组织。这将提升 QIAGEN 在可持​​续发展方面的声誉，并有可能吸引具有环保意识的客户和合作伙伴
  • 2023 年 11 月，QIAGEN 与 DNA Labs International 合作，使用 QIAGEN 的 ForenSeq Kintelligence 系统进行法医遗传谱系分析，结合 GEDmatch PRO 数据库，破获了两起长达数十年的悬案。这凸显了这种方法在人类身份识别方面的有效性和日益广泛的采用。这将提高 QIAGEN 法医遗传谱系分析解决方案的有效性，并有可能促进其在法医市场的采用和销售
  • 2022 年 6 月，Castle Biosciences, Inc. 是一家通过创新测试指导患者护理来改善健康的公司，该公司今天宣布已签署最终协议，收购 AltheaDx, Inc.。此次收购将有可能开发心理健康特许经营权，从目前获得医疗保险报销的抑郁症测试开始
  • 2022 年 5 月，Coriell Life Sciences 荣获第二届 MedTech 突破奖，以表彰其基因组学创新，引领了释放药物基因组学的力量以改善医疗保健。该组织的 Corigen 药物安全计划在 2022 年 MedTech 突破奖中被评为“最佳整体基因组学解决方案”。该奖项将使测试在用户中更具可信度

全球精神病学/抑郁症药物基因组学测试市场范围

全球精神病学/抑郁症药物遗传学测试市场根据类型、产品、测试类型、基因类型、患者类型、最终用户和分销渠道分为七个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

类型

  • 焦虑
  • 沮丧
  • 情绪障碍
  • 双相情感障碍
  • 饮食失调
  • 精神病

根据类型，全球精神病学/抑郁症药物基因组学测试市场分为焦虑、抑郁、情绪障碍、躁郁症、饮食失调和精神病。

产品

  • 耗材
  • 仪器
  • 软件和服务

根据产品，全球精神病学/抑郁症药物基因组学测试市场分为消耗品、仪器、软件和服务。

测试类型

  • 全基因组测序
  • 基于染色体阵列的测试

根据测试类型，全球精神病学/抑郁症药物基因组学测试市场分为全基因组测序和基于染色体阵列的测试。

基因类型

  • CYP2C19
  • CYP2C9 和 VKORC1
  • CYP2D6
  • HLA-B
  • 高温气冷堆2A/C
  • 人类白细胞抗原A
  • CYP3A4
  • SLC6A4
  • 亚甲基四氢叶酸还原酶
  • 通信技术
  • 其他的

根据基因类型，全球精神病学/抑郁症药物遗传学检测市场细分为 CYP2C19、CYP2C9 和 VKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT 等。

患者类型

  • 成人
  • 老年
  • 孩子

根据患者类型，全球精神病学/抑郁症药物基因组学测试市场分为成人、老年人和儿童。

最终用户

  • 医院和诊所
  • 诊断实验室
  • 学术及研究机构
  • 其他的

根据最终用户，全球精神病学/抑郁症药物基因组学测试市场分为医院和诊所、诊断实验室、学术和研究机构等。

分销渠道

  • 直接招标
  • 第三方分销
  • 医院药房
  • 其他的

根据分销渠道，全球精神病学/抑郁症药物基因组学测试市场分为直接招标、第三方分销、医院药房和其他。

精神病学/抑郁症市场中的药物基因组学测试

全球精神病学/抑郁症药物基因组学测试市场区域分析/见解

全球精神病学/抑郁症药物基因组学测试市场根据类型、产品、测试类型、基因类型、患者类型、最终用户和分销渠道分为七个显著的部分。

本市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、英国、法国、意大利、荷兰、西班牙、俄罗斯、瑞士、土耳其、波兰、挪威、匈牙利、奥地利、爱尔兰、立陶宛、欧洲其他地区、中国、日本、印度、韩国、澳大利亚、新加坡、泰国、印度尼西亚、马来西亚、菲律宾、越南、亚太其他地区、巴西、阿根廷、秘鲁、南美洲其他地区、沙特阿拉伯、阿联酋、以色列、南非、埃及以及中东和非洲其他地区。

随着北美地区抑郁症患者人数不断增加，北美有望主导全球精神病学/抑郁症药物基因组学测试市场。美国有望主导北美地区，因为制造商针对基因变异采取了强有力的举措。中国有望主导亚太地区，因为生物技术行业不断发展，医疗支出不断增加。德国有望主导欧洲地区，因为人们对个性化和精准医疗的兴趣日益浓厚。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战以及销售渠道的影响。

精神病学/抑郁症市场中的药物基因组学测试

全球精神病学/抑郁症药物基因组学测试市场竞争格局和份额分析

全球精神病学/抑郁症药物遗传学测试市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对全球精神病学/抑郁症药物遗传学测试市场的关注有关。

市场上的一些主要参与者包括 Thermo Fisher Scientific Inc.、Illumina Inc.、Myriad Genetics Inc.、Sonic Healthcare Limited、QIAGEN、AB-BIOTICS SA、BiogeniQ Inc.、Castle Bioscience Inc.、Coriell Life Sciences、Dynamic DNA Laboratories、Eurofins Scientific、Genelex、Genewiz、Genomind Inc.、GenXys、HealthSpek、HudsonAlpha、MD Labs、ONEOME LLC 和 PacBio 等。

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of Global pharmacogenetic testing in psychiatry/depression market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. market application coverage grid
    11. vendor share analysis
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
  5. REGULATIONS: GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
    1. UNITED STATES
      1. ROLE OF FDA
      2. ROLE OF CDC AND HCFA
    2. EUROPEAN UNION
    3. FRANCE
    4. AUSTRALIA
    5. SOUTH KOREA
  6. market overview
    1. drivers
      1. RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
      2. INITIATIVES TAKEN BY MANUFACTURERS
      3. GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
      4. INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
      5. GROWING MEDICAL TOURISM
    2. RESTRAINTS
      1. LACK OF STRONG CLINICAL EVIDENCE
      2. HIGH COST
      3. LACK OF REIMBURSEMENT
    3. OPPORTUNITIES
      1. TECHNOLOGICAL ADVANCEMENTS
      2. EMERGENCE OF NEW PLAYERS
      3. Untapped market
    4. CHALLENGES
      1. STRINGENT GOVERNMENT REGULATION
      2. SHORTAGE OF SKILLED PERSONNEL
  7. COVID-19 IMPACT ON GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY
    4. KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
    5. CONCLUSION:
  8. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
    1. overview
    2. WHOLE GENOME SEQUENCING
    3. array-based TESTS
  9. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
    1. overview
    2. cyp2c19
    3. CYP2C9 and VKORC1
    4. cyp2d6
    5. HLA-B
    6. htr2a/c
    7. HLA-A
    8. cyp3A4
    9. slc6a4
    10. MTHFR
    11. COMT
    12. others
  10. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
    1. overview
    2. PRESCRIPTION DRUGS
    3. Over-the-counter medications
    4. RECREATIONAL DRUGS
    5. VITAMINS/NUTRACEUTICals
  11. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
    1. overview
    2. SALIVA
    3. BLOOD
  12. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY application
    1. overview
    2. DRUG DEVELOPMENT
    3. CLINICAL PRACTICE
  13. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
    1. overview
    2. pharmaceutical and biotechnology companies
    3. HEALTHCARE PROVIDERS
    4. research centers and academic institues
    5. others
  14. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
    1. overview
    2. RETAIL PHARMACIES
    3. HOSPITAL PHARMACIES
    4. MAIL-ORDER PHARMACIES
    5. DIRECt-to-customer services
  15. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, by Geography
    1. overview
    2. north america
      1. u.s.
      2. canada
      3. mexico
    3. europe
      1. u.k.
      2. germany
      3. france
      4. italy
      5. spain
      6. netherlands
      7. belgium
      8. russia
      9. switzerland
      10. turkey
      11. rest of europe
    4. Asia-Pacific
      1. JAPAN
      2. cHINA
      3. SOUTH KOREA
      4. INDIA
      5. AUSTRALIA
      6. SINGAPORE
      7. THAILAND
      8. MALAYSIA
      9. indonesia
      10. philipPines
      11. rest of asia-pacific
    5. south america
      1. BRAZIL
      2. argentina
      3. rest of south america
    6. middle east & africa
      1. south africa
      2. saudi arabia
      3. uae
      4. israel
      5. egypt
      6. rest of middle east & africa
  16. Global Pharmacogenetic Testing in psychiatry/depression Market: COMPANY landscape
    1. company share analysis: Global
    2. company share analysis: North America
    3. company share analysis: Europe
    4. company share analysis: Asia-Pacific
  17. swot analysis
  18. company profile
    1. MYRIAD GENETICS, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. THERMO FISHER SCIENTIFIC INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    3. STADA ARZNEIMITTEL AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    4. sonic healthcare
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    5. Illumina, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    6. AB-Biotics, S.A.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. 6.3 PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    7. ALTHEADX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    8. biogeniq inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    9. Color
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    10. cnsdose
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    11. CORIELL LIFE SCIENCES
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    12. Dynamic DNA Laboratories
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    13. GENELEX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    14. genomind, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    15. genxys
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    16. HEALTHSPEK
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    17. HudsonAlpha Health Alliance (A Division of HudsonAlpha)
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    18. luminex corporation
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. MILLENNIUM HEALTH
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    20. mydna life australia pty ltd.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    21. oneome
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    22. OMECARE
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    23. PerkinElmer Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    24. R-Biopharm AG
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  19. questionnaire
  20. related reports

表格列表

TABLE 1 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD Million)

TABLE 2 Global Whole Genome Sequencing in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 3 Global Array-Based Tests in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 4 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD Million)

TABLE 5 Global CYP2C19 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 6 Global CYP2C9 AND VKORC1 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 7 Global CYP2D6 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 8 Global HLA-B in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 9 Global HTR2A/C in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 10 Global HLA-A in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 11 Global CYP3A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 12 Global SLC6A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 13 Global MTHFR in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 14 Global COMT in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 15 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD Million)

TABLE 17 Global PRESCRIPTION DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 18 Global OVER-THE-COUNTER MEDICATIONS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 19 Global RECREATIONAL DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 20 Global VITAMINS/NUTRACEUTICALS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD Million)

TABLE 22 Global Saliva in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 23 Global blood in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD Million)

TABLE 25 Global Drug Development in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 26 Global Clinical Practice in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD Million)

TABLE 28 Global Pharmaceutical & Biotechnology Companies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 29 Global Healthcare Providers in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 30 Global Research Centres And Academic Institutes in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 31 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD Million)

TABLE 33 Global Retail Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 34 Global Hospital Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 35 Global Mail-Order Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million))

TABLE 36 Global Direct-To-Customer Services in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 37 Global Pharmacogenetic Testing in psychiatry/depression Market , By Region, 2021-2028 (USD Million)

TABLE 38 north america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 39 north america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 40 north america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 41 north america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 42 north america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 43 north america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 44 north america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 45 north america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 46 u.s. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 47 u.s. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 48 u.s. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 49 u.s. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 50 u.s. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 51 u.s. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 52 u.s. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 53 canada pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 54 canada pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 55 canada pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 56 canada pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 57 canada pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 58 canada pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 59 canada pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 60 mexico pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 61 mexico pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 62 mexico pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 63 mexico pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 64 mexico pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 65 mexico pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 66 mexico pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 67 europe pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 68 europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 69 europe pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 70 europe pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 71 europe pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 72 europe pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 73 europe pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 74 europe pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 75 u.k. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 76 u.k. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 77 u.k. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 78 u.k. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 79 u.k. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 80 u.k. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 81 u.k. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 82 germany pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 83 germany pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 84 germany pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 85 germany pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 86 germany pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 87 germany pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 88 germany pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 89 france pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 90 france pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 91 france pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 92 france pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 93 france pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 94 france pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 95 france pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 96 italy pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 97 italy pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 98 italy pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 99 italy pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 100 italy pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 101 italy pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 102 italy pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 103 spain pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 104 spain pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 105 spain pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 106 spain pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 107 spain pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 108 spain pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 109 spain pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 110 netherlands pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 111 netherlands pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 112 netherlands pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 113 netherlands pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 114 netherlands pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 115 netherlands pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 116 netherlands pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 117 belgium pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 118 belgium pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 119 belgium pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 120 belgium pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 121 belgium pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 122 belgium pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 123 belgium pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 124 russia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 125 russia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 126 russia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 127 russia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 128 russia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 129 russia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 130 russia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 131 switzerland pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 132 switzerland pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 133 switzerland pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 134 switzerland pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 135 switzerland pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 136 switzerland pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 137 switzerland pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 138 turkey pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 139 turkey pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 140 turkey pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 141 turkey pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 142 turkey pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 143 turkey pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 144 turkey pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 145 rest of europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 146 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 147 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 148 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 149 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 150 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 151 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 152 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 153 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 154 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 155 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 156 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 157 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 158 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 159 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 160 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 161 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 162 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 163 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 164 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 165 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 166 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 167 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 168 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 169 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 170 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 171 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 172 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 173 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 174 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 175 India PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 176 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 177 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 178 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 179 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 180 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 181 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 182 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 183 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 184 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 185 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 186 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 187 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 188 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 189 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 190 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 191 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 192 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 193 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 194 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 195 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 196 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 197 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 198 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 199 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 200 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 201 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 202 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 203 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 204 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 205 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 206 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 207 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 208 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 209 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 210 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 211 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 212 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 213 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 214 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 215 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 216 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 217 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 218 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 219 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 220 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 221 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 222 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 223 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 224 Rest of Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 225 south america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 226 south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 227 south america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 228 south america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 229 south america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 230 south america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 231 south america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 232 south america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 233 brazil pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 234 brazil pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 235 brazil pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 236 brazil pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 237 brazil pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 238 brazil pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 239 brazil pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 240 argentina pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 241 argentina pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 242 argentina harmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 243 argentina pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 244 argentina pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 245 argentina pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 246 argentina pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 247 rest of south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 248 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 249 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 250 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 251 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 252 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 253 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 254 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 255 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 256 south africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 257 south africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 258 south africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 259 south africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 260 south africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 261 south africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 262 south africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 263 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 264 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 265 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 266 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 267 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 268 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 269 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 270 uae pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 271 uae pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 272 uae pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 273 uae pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 274 uae pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 275 uae pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 276 uae pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 277 israel pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 278 israel pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 279 israel pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 280 israel pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 281 israel pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 282 israel pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 283 israel pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 284 egypt pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 285 egypt pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 286 egypt pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 287 egypt pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 288 EGYPT pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 289 egypt pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 290 egypt pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 291 rest of middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

图片列表

FIGURE 1 Global PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION market: segmentation

FIGURE 2 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: data triangulation

FIGURE 3 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DROC ANALYSIS

FIGURE 4 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: global vs REGIONAL MARKET ANALYSIS

FIGURE 5 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: COMPANY RESEARCH ANALYSIS

FIGURE 6 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: INTERVIEW DEMOGRAPHICS

FIGURE 7 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL pharmacogenetic testing in psychiatry/depression MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 Global pharmacogenetic testing in psychiatry/depression market: vendor share analysis

FIGURE 10 Global pharmacogenetic testing in psychiatry/depression market: SEGMENTATION

FIGURE 11 initiatives taken by manufacturers is expected to drive THE Global pharmacogenetic testing in psychiatry/depression market IN THE FORECAST PERIOD of 2021 to 2028

FIGURE 12 whole genome sequencing segment is expected to account for the largest share of the Global pharmacogenetic testing in psychiatry/depression market in 2021 & 2028

FIGURE 13 NORTH AMERICA is expected to DOMINATE the gLOBAL pharmacogenetic testing in psychiatry/depression market and ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 asia-pacific is the fastest growing market for pharmacogenetic testing in psychiatry/depression manufacturers in the forecast period of 2021 to 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

FIGURE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028

FIGURE 17 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 18 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 19 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028

FIGURE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)

FIGURE 22 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)

FIGURE 23 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE

FIGURE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028

FIGURE 25 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)

FIGURE 26 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 28 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028

FIGURE 29 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)

FIGURE 30 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 31 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028

FIGURE 33 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 34 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 35 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028

FIGURE 37 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028

FIGURE 41 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 45 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020)

FIGURE 46 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2021 & 2028)

FIGURE 47 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020 & 2028)

FIGURE 48 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 49 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 50 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 51 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 52 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 53 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 54 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 55 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 56 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 57 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 58 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 59 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 60 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 61 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 62 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 63 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 64 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 65 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 66 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 67 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 68 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 69 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 70 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 71 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 72 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 73 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 74 Global Pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 75 North America pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 76 Europe pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 77 Asia-Pacific pharmacogenetic testing in psychiatry/DEPRESSION MARKET: company share 2020 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The major players in the Pharmacogenetics Testing in Psychiatry/Depression Market are Genelex (Part of Invitae corporation), Genewiz (Part of Azenta Life Sciences), MD Labs, BiogeneiQ, Inc., ONEOME, LLC, Myriad Genetics, Inc., GenXys, Castle Biosciences, Inc., PacBio, QIAGEN, etc.
The Pharmacogenetics Testing in Psychiatry/Depression Market growth rate is 10.4% during the forecast period.
The Pharmacogenetics Testing in Psychiatry/Depression Market growth rate is USD 2.66 billion by 2031 during the forecast period.
The type, product, test type, gene type, patient type, end user, and distribution channel are the factors on which the Pharmacogenetics Testing in Psychiatry/Depression Market research is based.
The latest developments in the Pharmacogenetics Testing in Psychiatry/Depression Market are Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, has acquired select assets from Intermountain Health's Precision Genomics (IPG) laboratory and QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research.

浏览相关页面

Banner